Revitope Oncology revitope.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Revitope Oncology is a cancer immunotherapy company developing a platform based on redirecting viral immunity for the purpose of developing compounds to treat solid tumors and hematologic malignancies. The company's technology redirects a viral immune response that already exists in order to treat cancer. Cancer patients typically have strong cytotoxic immunity against common viral pathogens, such as cytomegalovirus (CMV), but lack effective immunity against their tumors. Revitope's antibody pep...Show all

Revitope Oncology is a cancer immunotherapy company developing a platform based on redirecting viral immunity for the purpose of developing compounds to treat solid tumors and hematologic malignancies. The company's technology redirects a viral immun...Show all

Company (Alive / Active)

Phone: 617-500-0314

Fax:

700 Main Street, North

Cambridge, 02139
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Revitope Oncology $8.5M Feb 29, 2016

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Revitope Oncology Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells Nov 18, 2016 Application